Further to the National Patient Safety Alert issued on 28 November 2023, the purpose of this letter is to notify you of an important restriction of indication for new male patients and all female patients aged under 55 years, along with updated contraindications, warnings, and measures to prevent valproate exposure during pregnancy, as well as the availability of revised educational materials to support discussions with patients.